Laryngeal Preservation Rates in Patients Treated with Definitive or Concurrent Chemo radiation: Study in A high Volume Cancer Center

Introduction: The standard of care for patients with early-stage laryngeal cancer is radiotherapy and for locally progressed disease is concurrent chemo radiotherapy with cisplatin in all patients suitable for organ preservation. In patients not suitable for organ preservation surgery (Total laryngectomy) followed by radiotherapy is used. This organ saving treatment change from total laryngectomy to radiotherapy or concurrent chemoradiation has great impact on patients’ quality of life. Methods: This prospective study comprised a total of 100 patients. The typical follow-up time was one year. Patients with early-stage and locally progressed laryngeal carcinoma were randomly allocated to receive either radiotherapy alone or concurrent chemoradiation with cisplatin. The main goal was to keep the larynx intact. Results: Out of 100, Patients made up roughly 97% men and 3% women. Early stage groups made up 40% of the population, while locally advanced groups made up 59%. At one year, there had been no local relapse and in 89.6% of the patients larynx was preserved. It was shown that females had superior local control than males. Conclusions: These findings are significant, but it's important to keep in mind that irradiation is an effective method of treating these tumors, may have improved activity with modified fractionation or addition of simultaneous chemotherapy. Radiotherapy is a viable option to avoid total laryngectomy. On the other hand, new therapy options (biologic tools, imaging locations) and criteria for therapeutic success (quality of life, quality of maintained function, and cost-effectiveness) are emerging.